Increased Serum Concentration of Sphingosine-1-phosphate in Juvenile-onset Systemic Lupus Erythematosus

Watson, Louise; Tullus, Kjell; Marks, Stephen D.; Holt, Richard C. L.; Pilkington, Clarissa; Beresford, Michael W.

doi:10.1007/s10875-012-9710-3

Cited by 44 publications

(28 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Serum but not urine concentration of S1P was increased in 15 patients from the UK JSLE Cohort when compared with healthy controls [22]. Within the cSLE group, urinary levels of S1P did not differ between those with and without active kidney involvement nor did they correlate with standard disease activity measures.…”

Section: Biomarkersmentioning

confidence: 76%

An update on childhood-onset systemic lupus erythematosus

Barsalou

Levy²,

Silverman³

2013

Current Opinion in Rheumatology

View full text Add to dashboard Cite

show abstract

Section: Biomarkersmentioning

confidence: 76%

An update on childhood-onset systemic lupus erythematosus

Barsalou

Levy²,

Silverman³

2013

Current Opinion in Rheumatology

View full text Add to dashboard Cite

show abstract

“…As illustrated in Table 2A, endogenous LPLs were upregulated in the presence of metabolic and inflammatory disorders such as type 2 diabetes, diabetic retinopathy, acute coronary syndrome and autoimmune disorders. High serum levels of S1P, LPA and LPI was observed in patients with juvenile-onset systemic lupus erythematosus [47], proliferative diabetic retinopathy [48] and obese type 2 diabetes [49] respectively. Interestingly, acute coronary syndrome increased a bunch of pro-inflammatory LPLs (LPA, LPG, LPI and LPC) and anti-inflammatory LPLs (LysoPS and LPE).…”

Section: Resultsmentioning

confidence: 99%

Lysophospholipid Receptors, as Novel Conditional Danger Receptors and Homeostatic Receptors Modulate Inflammation—Novel Paradigm and Therapeutic Potential

Wang

Nanayakkara

et al. 2016

J. of Cardiovasc. Trans. Res.

View full text Add to dashboard Cite

There are limitations in the current classification of danger associated molecular patterns (DAMP) receptors. To overcome these limitations, we propose a new paradigm by using endogenous metabolites lysophospholipids (LPLs) as a prototype. By utilizing a data mining method we pioneered, we made the following findings: 1) Endogenous metabolites such as LPLs at basal level have physiological functions; 2) under sterile inflammation, expression of some LPLs are elevated. These LPLs act as conditional DAMPs or anti-inflammatory homeostasis-associated molecular pattern molecules (HAMPs) for regulating the progression of inflammation or inhibition of inflammation, respectively; 3) receptors for conditional DAMPs and HAMPs are differentially expressed in human and mouse tissues; and 4) complex signaling mechanism exists between pro-inflammatory mediators and classical DAMPs that regulate the expression of conditional DAMPs and HAMPs. This novel insight will facilitate identification of novel conditional DAMPs and HAMPs, thus promote development of new therapeutic targets to treat inflammatory disorders.

show abstract

“…A decrease in S1P level had previously been documented in acute dengue infection [13], sepsis [16], chronic hepatitis C infection [21] and obesity [14]. In contrast, elevated serum level of S1P has been previously reported in autoimmune and inflammatory diseases, including juvenile-onset systemic lupus erythematosus [15] and systemic sclerosis [22]. In human malaria, S1P levels have been showed to decrease significantly in Ugandan children with cerebral malaria [12].…”

Section: Discussionmentioning

confidence: 99%

Reduction in serum sphingosine 1-phosphate concentration in malaria

Punsawad

Viriyavejakul

2017

PLoS ONE

View full text Add to dashboard Cite

Sphingosine 1-phosphate (S1P) is a lipid mediator formed by the metabolism of sphingomyelin which is involved in the endothelial permeability and inflammation. Although the plasma S1P concentration is reportedly decreased in patients with cerebral malaria, the role of S1P in malaria is still unclear. The purpose of this study was to examine the impact of malaria on circulating S1P concentration and its relationship with clinical data in malaria patients. Serum S1P levels were measured in 29 patients with P. vivax, 30 patients with uncomplicated P. falciparum, and 13 patients with complicated P. falciparum malaria on admission and on day 7, compared with healthy subjects (n = 18) as control group. The lowest level of serum S1P concentration was found in the complicated P. falciparum malaria group, compared with P. vivax, uncomplicated P. falciparum patients and healthy controls (all p < 0.001). In addition, serum S1P level was positively correlated with platelet count, hemoglobin and hematocrit levels in malaria patients. In conclusions, low levels of S1P are associated with the severity of malaria, and are correlated with thrombocytopenia and anemia. These findings highlight a role of S1P in the severity of malaria and support the use of S1P and its analogue as a novel adjuvant therapy for malaria complications.

show abstract

Increased Serum Concentration of Sphingosine-1-phosphate in Juvenile-onset Systemic Lupus Erythematosus

Abstract: We have demonstrated, for the first time, an increased serum concentration of S1P in a cohort of JSLE patients. These findings highlight a role of S1P in the pathophysiology of JSLE that warrants further investigation.

Cited by 44 publications

References 39 publications

An update on childhood-onset systemic lupus erythematosus

An update on childhood-onset systemic lupus erythematosus

Lysophospholipid Receptors, as Novel Conditional Danger Receptors and Homeostatic Receptors Modulate Inflammation—Novel Paradigm and Therapeutic Potential

Reduction in serum sphingosine 1-phosphate concentration in malaria

Contact Info

Product

Resources

About